Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atlas Air Worldwide

CoreLogic

Dollar General

General Mills

Amid coronavirus concerns and Q1 earnings in full swing, it is advisable to follow broker ratings to find attractive stocks.

5 Stocks to Add to Your Portfolio on Upgraded Broker Ratings

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q1 2020 Results - Earnings Call Transcript

West Pharmaceutical (WST) delivered earnings and revenue surprises of 23.17% and 5.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates

MarketAxess Holdings

Bull market, bear market, it doesn’t matter: Underappreciated, under-covered companies always manage to make a splash.

3 Dividend Growers You Can’t Ignore Anymore

West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can West Pharmaceutical (WST) Keep the Earnings Surprise Streak Alive?

Costco

Deckers Outdoor

Principal Financial Group

WNS Holdings Ltd

Higher debt financing is never desirable. So, an investor's portfolio should include stocks that are not highly leveraged.

Buy These 5 Low Leverage Stocks Amid Coronavirus Outbreak

West Pharmaceutical Services shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stocks To Watch: West Pharmaceutical Services Sees RS Rating Jump To 93 appeared first on Investor's Business Daily.

Stocks To Watch: West Pharmaceutical Services Sees RS Rating Jump To 93

West Pharmaceutical Services' (WST) CEO Eric Green on Q4 2019 Results - Earnings Call Transcript

West Pharmaceutical (WST) delivered earnings and revenue surprises of 13.89% and 4.07%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Q4 Earnings and Revenues Top Estimates

Cerner

HMS Hlds

LHC Group

Omnicell

We have zeroed in on five impressive growth stocks in MedTech on the back of the industry's lucrative prospects.

5 Promising Growth Stocks in MedTech to Invest in 2020

Patterson Companies

PDCO vs. WST: Which Stock Is the Better Value Option?

PDCO or WST: Which Is the Better Value Stock Right Now?

CONMED

DexCom

NuVasive

ResMed

Tandem Diabetes Care

Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

6 MedTech Stocks That are Set to Beat the Market in 2020

DENTSPLY SIRONA

XRAY vs. WST: Which Stock Is the Better Value Option?

XRAY or WST: Which Is the Better Value Stock Right Now?

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q3 2019 Results - Earnings Call Transcript

West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

West Pharmaceutical (WST) Hits Fresh High: Is There Still Room to Run?

Manhattan Associates

These mid-cap plays are firing on all cylinders, hitting all-time highs in this tough summer trading environment.

3 Mid-Caps Hitting New Highs

Edwards Lifesciences

The charts for these three stocks show the kinds of curves that investors should really like -- trending upward.

Forget the Inverted Yield Curve, These 3 Stocks Just Hit All-Time Highs

As of late, it has definitely been a great time to be an investor West Pharmaceutical.

Will West Pharmaceutical Continue to Surge Higher?

West Pharmaceutical Services's (WST) CEO Eric Green on Q2 2019 Results - Earnings Call Transcript

West Pharmaceutical (WST) delivered earnings and revenue surprises of 23.61% and 1.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Beats Q2 Earnings and Revenue Estimates

Baxter

Labcorp Holdings Inc

Stryker

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

Henry Schein

HSIC vs. WST: Which Stock Is the Better Value Option?

HSIC vs. WST: Which Stock Should Value Investors Buy Now?

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q1 2019 Results - Earnings Call Transcript

Federal Realty Investment Trust

W.W. Grainger

Coca-Cola

Tanger Factory Outlet Centers

To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years.

News for West Pharmaceutical Services Stock (WST)